PhD Scientific Days 2023
Budapest, 22-23 June 2023
Clinical Medicine V.
Early versus Delayed Enteral Nutrition in Patients after Gastrointestinal Bleeding: Meta-analysis of Randomized Controlled Trials
Előadó neve
Dr. Obeidat, Mahmoud
Neptun code
SL8LR6
Előadó munkahelye
Semmelweis University, Centre for Translational Medicine
Előadó telefonszáma
+36202809816
Előadó e-mail címe
obeidat.mahmoud@phd.semmelweis.hu
Az előadás címe
Early versus Delayed Enteral Nutrition in Patients after Gastrointestinal Bleeding: Meta-analysis of Randomized Controlled Trials
Szerző(k) neve és munkahelye
Mahmoud Obeidat (1,2), Brigitta Teutsch (1,2), Diana Iov (1,3), Dániel Sándor Veres (1,4), Péter Hegyi (1,2,5), Bálint Erőss (1,2,5)
1- Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
2- Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
3- Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
4- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
5- Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary
Bemutatás módja
Szóbeli
Szekció
Clinical Medicine V.
Language of the presentation
English
Preferred session
Clinical Medicine
Összefoglaló szövege
INTRODUCTION
Despite lack of evidence, patients are kept nil by mouth for 48 to 96 hours after upper gastrointestinal bleeding (UGIB) due to fear of rebleeding. However, many trials have demonstrated the benefits of early enteral nutrition (EEN) after UGIB.
AIMS
We conducted a meta-analysis of randomized controlled trials to evaluate the safety and outcomes of EEN compared to delayed enteral nutrition (DEN) after UGIB.
METHODS
The protocol was registered on PROSPERO in advance (CRD42022372306). Five databases (PubMed, Embase, CENTRAL, Scopus, and Web of Science) were searched on the 10th of November 2022 to identify randomized controlled trials that met our eligibility criteria. In-hospital and 30-day outcomes were pooled separately. Mortality rate, rebleeding rate, and length of hospital stay were the primary outcomes. The pooled risk ratio (RR), mean difference (MD), and the corresponding 95% confidence interval (CI) were calculated using a random-effects model.
RESULTS
A total of 10 trials with 1,051 patients were included in the analysis. Compared with DEN, there was a clear tendency for a decrease in 30-day mortality in the EEN group (RR=0.57, CI: 0.31 – 1.04), while 7-day mortality showed a more similar result (RR=1.23, CI: 0.72 - 2.10). As for 7-day and 30-day rebleeding, there was no statistically significant difference between the two groups (RR=1.05, CI: 0.63 – 1.74 and RR=1.16, CI: 0.59 – 2.26, respectively). In addition, our analysis showed that the EEN group needed a reduced length of hospital stay compared to the DEN group (MD= - 1.22, CI: -2.43 to -0.01).
CONCLUSION
Compared with DEN, EEN appears to be a safe intervention and could reduce the length of hospital stay without increasing the risk of complications regarding rebleeding or mortality after upper gastrointestinal bleeding.
University and Doctoral School
Semmelweis University, Doctoral School of Pharmaceutical Sciences
Supervisor
Bálint Erőss
Publication of my abstract
I give consent to the publication of my abstract on the website of the congress.
Kind
Szabad
Status
elfogadva
Accepted presentation method
szóbeli
Előadás fájl jóváhagyás
nem rendelkezett róla
Előadó
6805
Start
14:45
End
15:00
Authors (legacy)
Mahmoud Obeidat (1,2), Brigitta Teutsch (1,2), Diana Iov (1,3), Dániel Sándor Veres (1,4), Péter Hegyi (1,2,5), Bálint Erőss (1,2,5)
1- Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
2- Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
3- Grigore T. Popa University of Medicine and Pharmacy, Iași, Romania
4- Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
5- Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary